Copenhagen Study of Obese Patients With Ischemic Heart Disease Undergoing Low Energy Diet or Interval Training

NCT01724567 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2014-08-05

No results posted yet for this study

Summary

The purpose of the study is to make a head-to-head comparison of weight loss and interval training as methods of secondary prevention in overweight patients with ischemic heart disease.

Conditions

Interventions

OTHER

Interval Training

Interval training (IT) on an exercise bike 3 times a week, for the first 12 weeks, followed by 40 weeks of IT 2 times a week on exercise bike. Each training session consists of active intervals with a total duration of 16 minutes (durations intervals between 1 and 4 minutes) at 90% of maximal heart rate. Active intervals are separated by active pauses at 60% of maximal heart rate.

OTHER

Weight Loss

Low calorie diet approx. 1000 kcal/day for 8 - 10 weeks to obtain a 10 - 15 % weight loss.

Sponsors & Collaborators

  • University of Copenhagen

    collaborator OTHER
  • Amager Hospital

    collaborator OTHER
  • Bispebjerg Hospital

    collaborator OTHER
  • Copenhagen University Hospital at Herlev

    collaborator OTHER
  • Copenhagen University Hospital, Hvidovre

    collaborator OTHER
  • Rigshospitalet, Denmark

    collaborator OTHER
  • University of California, Davis

    collaborator OTHER
  • Texas A&M University

    collaborator OTHER
  • University of Aarhus

    collaborator OTHER
  • Eva Prescott

    lead OTHER

Principal Investigators

  • Eva Prescott, MD, DMsc · Bispebjerg Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01724567 on ClinicalTrials.gov